


# DAC<sup>®</sup>

DEFENSIVE ANTIBACTERIAL COATING



**SCIENTIFIC REFERENCES SUMMARY**

**2021**

RATIONALE AND INTENDED USE .....	3
<i>IN VITRO</i> DATA .....	5
<i>IN VIVO</i> DATA .....	10
CLINICAL DATA .....	13
ASSESSMENT OF DAC® USAGE IMPACT ON HEALTHCARE COSTS .....	22
References .....	24

In spite of systemic antibiotic prophylaxis, **implant-related infection remains one of the leading reasons for failure of joint replacements and of internal osteosynthesis**, with extremely high social and economic associated costs (cf. Table 1). [1]

**Table 1. Impact of implant-related infections in orthopaedics and trauma: facts and numbers.**

<p><b>Infection risk after joint arthroplasty:</b> the incidence of peri-prosthetic joint infection (PJI) ranges from 1 to 2% after primary implant and up to 10% after revision surgery and in oncological reconstructions; [3]</p> <p><b>Infection risk after osteosynthesis:</b> the incidence of surgical site infection (SSI) after osteosynthesis for closed fractures of the long bones ranges from 2% to 10% [2]. The incidence of SSI after open fractures of the long bones is more than 20%; [3]</p>
<p><b>Leading reason for revision:</b> Peri-prosthetic hip and knee infection is among the first three reasons for joint replacement failure, according to the registers; [4]</p>
<p><b>Mortality risk:</b> the adjusted relative mortality risk (RR) for patients with hip revision for PJI, compared with the patients who did not undergo revision surgery is 2.18 [5]. The RR for patients undergoing hip revision for PJI, compared with aseptic hip revision, ranges from 1.87 to 3.10; [6]</p>
<p><b>Additional costs:</b> the average cost of management of infection after hip fracture surgery is &gt; 30,000 Euros. [6] The cost for the management of any single case of hip or knee PJI ranges from 40,000 to &gt; 100,000 Euros. [7, 8]</p>

All implant-associated infections share complex diagnostic and treatment procedures, due to the presence of bacterial biofilm(s) and slow-growing, persistent microorganisms, able to even survive into the host's cells and often resistant to most or all of the available antibiotics.

**Given its challenging treatment, prevention is pivotal in reducing the periprosthetic joint infection burden.**

To this aim, providing implanted biomaterials with an antibacterial coating or finishing has been advocated by experts and respected institutions as one of the most promising solutions, in order to mitigate the impact of septic complications. [9]

In line with this vision, the “Defensive Antibacterial Coating” (DAC®, Novagenit Srl, Mezzolombardo, Italy) has been specifically designed to protect from bacterial colonization and biofilm formation a wide variety of implantable biomaterials used in orthopaedics, traumatology, dentistry and maxillofacial surgery.

The biodegradable hydrogel is intended to serve as a temporary physical barrier against the bacterial adhesion and the formation of microbial biofilms.

DAC® represents an additional measure of infection prevention, which is not intended to replace or to substitute the asepsis measures and the usual protocols of antibiotic prophylaxis recommended in orthopedic surgery.

This “White Paper” is aimed at providing a comprehensive review of the evidence related to the preclinical and clinical results in orthopaedics and trauma \*.

In particular, evidence will be provided concerning the following statements:

- **DAC® IS MADE OF HIGHLY BIOCOMPATIBLE POLIMERS**
- **DAC® IS SAFE ACCORDING TO *IN VITRO* RESULTS**
- **DAC® HAS A PROVEN ANTIBIOFILM ACTIVITY**
- **DAC® IS EFFECTIVE AND SAFE *IN VIVO***
- **DAC® PROVIDES AN AVERAGE 8 TIMES REDUCTION OF POST-SURGICAL IMPLANT-RELATED INFECTIONS IN ORTHO-TRAUMA**
- **NO SIDE EFFECTS REPORTED**
- **DAC® IS ASSOCIATED WITH A FAVORABLE COST-BENEFIT-RATIO**

For more information, you may also visit:



[www.dac-coating.com](http://www.dac-coating.com)




[www.novagenit.com](http://www.novagenit.com)

\* Not all available studies on DAC® technology are included in this White Paper.

# DAC<sup>®</sup>

DEFENSIVE ANTIBACTERIAL COATING



## ***IN VITRO DATA \****

\* ALL THE CLINICAL PAPERS SUMMARIZED IN THIS SECTION CAN BE FOUND AND REVIEWED IN THE "SCIENTIFIC REFERENCES" SECTION OF THE DAC<sup>®</sup> WEBSITE [WWW.DAC-COATING.COM](http://WWW.DAC-COATING.COM)

## Chemical structure

Composed of covalently linked hyaluronan (HA) and poly-D,L-lactide (PLA) (**Fig. 1**), the “Defensive Antibacterial Coating” (DAC<sup>®</sup>, Novagenit Srl, Mezzolombardo, Italy) has been specifically developed in order to protect implanted biomaterials used in orthopaedics, traumatology, dentistry and maxillofacial surgery from bacterial colonization. [10,11]




Fig. 1. Chemical structure of the HA-g-PLA copolymer

As a medical device, DAC<sup>®</sup> is in the form of a kit, composed of a sterile, double-sealed syringe, containing a powder, intended to be mixed at the time of surgery with a water-based solution to form the hydrogel; also provided are accessories, suitable to apply the hydrogel coating on the surface of the implants.

DAC<sup>®</sup> is composed by highly biocompatible and fully resorbable biopolymers.

## Cell compatibility assay

*In vitro* cell compatibility of DAC<sup>®</sup> HA-g-PLA hydrogel (polymer concentration 6%, w/v) was evaluated using human dermal fibroblasts. The viability of cells cultured in direct or indirect contact with HA-g-PLA hydrogel was comparable with that of the control well, showing that the hydrogel does not release in the culture medium substances that interfere with cell viability and they do not cause a decrease in the cell viability after direct contact with them. [10]

Further *in vitro* and *in vivo* biocompatibility studies were performed on the DAC<sup>®</sup> hydrogel and on the DAC<sup>®</sup> kit, in accordance to ISO standards, all showing no cytotoxicity, genotoxicity, sensitization, irritation or intracutaneous reactivity, systemic toxicity (acute), subchronic toxicity or interference with bone or peri-implant tissues (Novagenit Srl, data on file).

Furthermore, as degradation of DAC<sup>®</sup> HA-g-PLA hydrogel occurs via deesterification of hyaluronic acid and polylactic acid, it gives rise exclusively to the starting macromolecules, whose degradation pathways in the human body are widely known and whose use as implantable class III medical devices is largely accepted and tested safe.

DAC<sup>®</sup> showed full *in vitro* biocompatibility.

In the human body the DAC<sup>®</sup> hydrogel gives rise only to tested safe macromolecules.



## Antiadhesive and antibiofilm activity


The mechanism of action is related to the antifouling and antiadhesive properties of hyaluronic acid.

Both the ability of the DAC® HA-g-PLA hydrogel to reduce bacterial adhesion and biofilm formation were extensively studied *in vitro*.


**Reductions of adhered bacteria on sterile titanium discs, coated with DAC® hydrogel, equal to 86.8, 80.4, 74.6 and 66.7% vs. untreated discs were observed after 15, 30, 60 and 120 min of incubation, respectively [12] (Fig. 2).**

In another experiment, the ability to dislodge previously adhered bacteria was investigated.


Once again, the results showed that **DAC® hydrogel treatment of discs reduced the amount of adhered bacteria in respect to control discs after 15, 30, 60 and 120 min by 84.0, 72.8, 72.3 and 64.3%, respectively (Fig. 2-5). [12]**




**Figure 2.** Adhesion densities of *S. aureus* (mean CFU/cm<sup>2</sup> ± standard deviation) to discs pre-treated with DAC® (“Defensive Antibacterial Coating”, Novagenit Srl, Mezzolombardo, Italy) and controls at 15, 30, 60 and 120 min; \*\*\* P < 0.001 (two-way ANOVA followed by Bonferroni post hoc test). [12]



**Figure 3.** Adhesion densities of *S. aureus* (mean CFU/cm<sup>2</sup> ± standard deviation) over time in pre-treated with DAC® and control discs at 15, 30, 60, 120 min; \* 0.01 < P < 0.05, \*\* 0.001 < P < 0.01, \*\*\* P < 0.001 (two-way ANOVA followed by Bonferroni post hoc test). [12]



**Figure 4.** Adhesion densities on discs with of *S. aureus* (mean CFU/cm<sup>2</sup> ± standard deviation) applied before DAC® treatment and controls at 15, 30, 60, 120 min; \* 0.01 < P < 0.05, \*\*\* P < 0.001 (two-way ANOVA followed by Bonferroni post hoc test). [12]




**Figure 5.** Adhesion densities over time on discs with of *S. aureus* (mean CFU/cm<sup>2</sup> ± standard deviation) applied before DAC® treatment and controls at 15, 30, 60, 120 min; \* 0.01 < P < 0.05, \*\* 0.001 < P < 0.01, \*\*\* P < 0.001 (two-way ANOVA followed by Bonferroni post hoc test). [12]

Concerning more specifically the antibiofilm activity, **DAC® hydrogel showed similar or superior *in vitro* activity, compared to various antibacterials and a synergistic activity when used in combination.** [11]

In one experimental setting, *S. epidermidis* and *S. aureus* were grown on chrome-cobalt devices in 6-wells polystyrene plates containing TSB for 24 h at 37°C. The plates were incubated at 37°C in ambient air, until a visible biofilm was obtained. Gentamycin and vancomycin were tested at a final concentration of 20 mg/mL. Similarly, when mixed with the hydrogel, 60 mg of gel powder was reconstituted with 1 mL of water for injections containing gentamicin or vancomycin at 20 mg/mL concentration. The amount of biofilm at each time was determined before hydrogel and antibiotic agents' addition and after 0.5, 1, 2, 4, 6, 24 and 48 h of incubation by a spectrophotometric assay.

At each time point, both gentamicin and vancomycin showed only a partial inhibition of biofilm formation (ca. 30–40% for gentamicin; ca. 40–50% for vancomycin), with minor difference between the two studied microorganisms.

On the other side, the hydrogel alone resulted in a significant reduction of biofilm of ca. 50%, in comparison to the untreated controls, while a combination of the hydrogel with either antibacterial coating resulted in a larger reduction of biofilm formation (approximately 75–80% in comparison with untreated controls) (Fig. 6). [12]



**Figure 6.** Comparison of the efficacy of DAC® hydrogel, gentamicin, vancomycin or a combination thereof, on biofilm formation reduction of *Staphylococcus aureus* (A. and B.) and *Staphylococcus epidermidis* (C. and D.) over time (hours). Note that **the hydrogel alone is able to provide an equal or superior biofilm reduction compared to commonly used antibiotics**, while a synergistic effect is observed using a combination of the hyaluronic acid based hydrogel and the antibiotic compounds. [12]

DAC® Hydrogel coating has a proven antiadhesive and antifilm activity.

When combined with vancomycin or gentamycin, the DAC® hydrogel shows a synergistic antifilm activity.



## Rationale for the intra-operative DAC<sup>®</sup> hydrogel antibiotic loading

Preclinical studies have demonstrated the ability of the DAC<sup>®</sup> hydrogel to significantly reduce bacterial adhesion and biofilm formation of common bacterial pathogens, thus providing an effective protection of the implant.

According to this model, the antiadhesive hydrogel coating acts as a tool to reduce and delay bacterial adhesion and biofilm formation to a variable degree, depending on the local environment, the bacterial species and the bacterial load; **this activity of the coating may represent a key additional advantage to the host's cells to win the competition with the microorganisms that may eventually be present.**


Reducing the ability of bacteria to adhere to the implant **will decrease the chance of bacterial colonization and infection, provided that the immune system and eventually the systemically administered antibiotic are able to kill the microorganisms in their planktonic state.**

However, **since the hydrogel coating has no bactericidal activity**, it may be anticipated that, **whenever the immune system should fail to destroy the planktonic microorganisms, these may still have the chance to colonize the implant and the surrounding tissues at a later stage**, when the coating will be hydrolyzed or covered by the host's proteins.

This observation supports the ancillary function exerted by the antibiotic(s), that may be loaded intra-operatively to the DAC<sup>®</sup> hydrogel, in order to minimize the possibility for planktonic bacteria, which may eventually remain in the local environment, to overcome the anti-fouling coating of the implant at a later stage, once the coating hydrolysis proceeds (Fig. 7). [13]

Furthermore, several studies have shown i. the ability of the hydrogel to be loaded and to completely release all the tested antibiotics in less than 72 hours; ii. The synergistic effect of the hydrogel + antibiotic, compared to either component alone [11]; iii. The absence of any measurable side effects of the antibiotic-loaded DAC<sup>®</sup> hydrogel coating both in preclinical [14,15] and in all available clinical studies [cf. Clinical Data - Safety].

**Figure 7.** Rationale for intra-operative mixing of DAC<sup>®</sup> hydrogel coating with antibacterial agents. Schematic representation of different scenarios. (a) Noncoated implants may get colonized by biofilm-forming bacteria (yellow circles) and infection will develop. (b) Antiadhesive coating may reduce/prevent bacterial adhesion, while the immune system (orange circles and red stars) and the systemically administered antibiotics (blue star) kill planktonic microorganisms. (c) However, if bacterial load is large enough, or if immune response and local antibiotic levels are inadequate, surviving bacteria may eventually colonize the implant, once the coating has been hydrolyzed or covered by host's proteins. (d) To prevent this, the antibacterial hydrogel may be loaded, at the time of surgery, with antibiotic agents (blue stars) that may be locally released, contributing to eliminate all remaining planktonic bacteria. [13]



# DAC<sup>®</sup>

DEFENSIVE ANTIBACTERIAL COATING



## ***IN VIVO DATA \****

\* ALL THE CLINICAL PAPERS SUMMARIZED IN THIS SECTION CAN BE FOUND AND REVIEWED IN THE "SCIENTIFIC REFERENCES" SECTION OF THE DAC<sup>®</sup> WEBSITE [WWW.DAC-COATING.COM](http://WWW.DAC-COATING.COM)

## Efficacy of antibacterial-loaded coating in an in vivo model of acutely highly contaminated implant

Gianluca Giavaresi • Enzo Meani • Maria Sartori • Andrea Ferrari •  
Davide Bellini • Anna C. Sacchetta • Joachim Meraner • Andrea Sambri •  
Caterina Vocale • Vittorio Sambri • Milena Fini • Carlo L. Romanò

Received: 17 November 2013 / Accepted: 26 November 2013 / Published online: 22 December 2013  
© The Author(s) 2013. This article is published with open access at Springerlink.com


**Methods** A histocompatibility study was performed in 10 adult New Zealand rabbits. Then, methicillin-resistant *Staph. aureus* were inoculated in the femur of 30 adult New Zealand rabbits at the time of intra-medullary nailing; vancomycin-loaded DAC® coated nails were compared to controls regarding local and systemic infection development.

**Results** Histocompatibility study showed **no detrimental effect of DAC® hydrogel on bone tissue after 12 weeks from implant.**

After seven days from implant, none of the rabbits receiving vancomycin-loaded DAC® nail showed positive blood cultures, compared to all the controls; **vancomycin-loaded DAC® coating was associated with local bacterial load reduction ranging from 72 to 99 %, compared to controls.**

### Conclusions

Vancomycin-loaded DAC® coating is able to **significantly reduce bacterial colonization in an animal model of an intra-operatively highly contaminated implant, without local or general side effect.** [14]



**Fig. 1** Release of vancomycin from DAC® hydrogel at defined intervals during incubation at 37 °C. Release expressed as percentage of total antibiotic quantity loaded

More than 80% of the antibiotic is released in the first 24 hours from the **DAC® hydrogel.**

This observation is in line with that observed in in vitro studies, showing complete antibiotic release within 72 hours.

The fast and complete antibiotic release provides the best antibacterial activity, minimizing the risk of antibiotic resistance induction.

## Research Article

### Systemic and Local Administration of Antimicrobial and Cell Therapies to Prevent Methicillin-Resistant *Staphylococcus epidermidis*-Induced Femoral Nonunions in a Rat Model

Arianna B. Lovati,<sup>1</sup> Lorenzo Drago,<sup>2,3</sup> Marta Bottagisio,<sup>1,4</sup>  
Matilde Bongio,<sup>1</sup> Marzia Ferrario,<sup>5</sup> Silvia Perego,<sup>6</sup> Veronica Sansoni,<sup>6</sup>  
Elena De Vecchi,<sup>2</sup> and Carlo L. Romano<sup>7</sup>

<sup>1</sup>Cell and Tissue Engineering Laboratory, IRCCS Galeazzi Orthopaedic Institute, 20161 Milan, Italy

<sup>2</sup>Laboratory of Clinical Chemistry and Microbiology, IRCCS Galeazzi Orthopaedic Institute, 20161 Milan, Italy

<sup>3</sup>Department of Biomedical Science for Health, University of Milan, 20133 Milan, Italy

<sup>4</sup>Department of Veterinary Medicine (DiMeVet), University of Milan, 20133 Milan, Italy

<sup>5</sup>MAP Laboratory, Fondazione Filarete, 20139 Milan, Italy

<sup>6</sup>Laboratory of Experimental Biochemistry & Molecular Biology, IRCCS Galeazzi Orthopaedic Institute, 20161 Milan, Italy

<sup>7</sup>Department of Reconstructive Surgery of Osteoarticular Infections, CRIO Unit, IRCCS Galeazzi Orthopaedic Institute, 20161 Milan, Italy

Microbiological detection of bacterial growth on the explanted specimens.

Comparisons among groups were analyzed with one-way ANOVA corrected with Bonferroni's *post hoc* test. Statistical significance was  $p < 0.01$  (\*\*), and  $p < 0.001$  (\*\*\*);  $n = 6$ . At 42 days from surgery, DAC® hydrogel enriched with vancomycin at 5% (v/w) (I-VANC), distributed on plates and screws during the osteosynthesis, shows nearly undetectable bacterial growth, which is significantly lower than that observed in controls without the coating (PC) and even lower than that observed in systemically administered vancomycin (s-VANC).

Forty-two days after surgery, 50% of the DAC® hydrogel coated osteosynthesis showed bone healing at the fracture site, compared to 0 % and 33 % in the control and s-VANC groups, respectively, demonstrating a clear **protective effect of the coating on bone healing**. [15]


	Bony bridging > 75% fracture healing
Controls	0 %
s-VANC	33 %
I-VANC	50 %

In this Animal model DAC® Hydrogel coating applied to internal osteosynthesis provided a protection against infected non-unions.



# DAC®

DEFENSIVE ANTIBACTERIAL COATING



## CLINICAL DATA \*

\* ALL THE CLINICAL PAPERS SUMMARIZED IN THIS SECTION CAN BE FOUND AND REVIEWED IN THE "SCIENTIFIC REFERENCES" SECTION OF THE DAC® WEBSITE [WWW.DAC-COATING.COM](http://WWW.DAC-COATING.COM)





## Research Paper

# Does an Antibiotic-Loaded Hydrogel Coating Reduce Early Post-Surgical Infection After Joint Arthroplasty?

Carlo Luca Romano<sup>1</sup>, Kostantinos Malizos<sup>2</sup>, Nicola Capuano<sup>3</sup>, Riccardo Mezzoprete<sup>4</sup>, Michele D'Arienzo<sup>5</sup>, Catherine Van Der Straeten<sup>6,7</sup>, Sara Scarponi<sup>1</sup> and Lorenzo Drago<sup>8,9</sup>

1. Department of Reconstructive Surgery of Osteo-articular Infections C.R.I.O. Unit, I.R.C.C.S. Galeazzi Orthopaedic Institute, Milano, Italy.
2. Orthopaedic Surgery & Trauma, Medical School, University of Thessaly, Larissa, Greece.
3. Department of Orthopaedics, San Luca Hospital - Vallo della Lucania, Italy.
4. Department of Orthopaedics, San Camillo de Lellis Hospital - Rieti, Italy.
5. Orthopaedic Surgery & Trauma, University Clinic, Palermo, Italy.
6. Department of Orthopaedics, Medical University Ghent, Belgium.
7. MSK Lab, Department of Surgery and Cancer, Imperial College London, London, United Kingdom.
8. Clinical Chemistry and Microbiology Laboratory, I.R.C.C.S. Galeazzi Orthopaedic Institute, Milano, Italy.
9. Laboratory of Medical Technical Sciences, Department of Biochemical Sciences for Health, University of Milano, Italy.

## Study profile:

- Condition: Total hip or knee joint replacement
- Intervention: Intraoperative application DAC<sup>®</sup> + Antibacterial Agent
- Study design: Single blind - randomized - controlled - multicenter
- Endpoint classification: safety and efficacy study
- Primary outcome measures:
  - clinical and laboratory evidence of safety
  - clinical and laboratory evidence of efficacy
- Level of evidence II


## Study population:

373 patients

- 189 treated group - prosthesis and DAC<sup>®</sup>
  - 184 control group - prosthesis
- Mean age (years): 71 ± 10.6 (control)  
Mean age (years) 69 ± 12.6 (treated)A


## Risk profile:

In both groups 76% of the patients presented with one or more relevant co-morbidity known to increase postsurgical infection risk (McPherson's classification)

DAC<sup>®</sup> Effectiveness

## Evidence :

11 surgical site infections were reported in the control group (6%), compared to only one (0.6%) in the treated group (P=0.003) at 14.5 months follow-up



TREATED PATIENT					
HOST TYPE	RELEVANT CO-MORBIDITIES	PRE-OPERATIVE DIAGNOSIS	ONSET OF INFECTION (MONTHS FROM SURGERY)	CULTURAL EXAMINATION	TREATMENT
B	DIABETES; BMI > 40	HIP OSTEO-ARTHRITIS	< 1	NEGATIVE CULTURES	NO FURTHER INFECTION RECURRENCE

13.5% (7/52) of control group second stage revision developed surgical site infection vs 0% (0/54) in the treated group. 3% (4/132) of control group primary surgery developed SSI vs 0% (0/135) in the treated group.

**Conclusions** The patient population presents an incidence of high risk factors. Results showed 6% infection in the control group, versus 0.5% occurrence of infection in the treated group (P<0.003).

# Fast-resorbable antibiotic-loaded hydrogel coating to reduce post-surgical infection after internal osteosynthesis: a multicenter randomized controlled trial

Kostantinos Malizos<sup>1</sup> · Michael Blauth<sup>2</sup> · Adrian Danita<sup>2</sup> · Nicola Capuano<sup>3</sup> · Riccardo Mezzoprete<sup>4</sup> · Nicola Logoluso<sup>5</sup> · Lorenzo Drago<sup>6,7</sup> · Carlo Luca Romano<sup>5</sup>

✉ Carlo Luca Romano  
carlo.romano@grupposandonato.it

Kostantinos Malizos  
kmalizos@otenet.gr

Michael Blauth  
michael.blauth@i-med.ac.at

Adrian Danita  
adrian.danita@tirol-kliniken.at

Nicola Capuano  
capuano.nicola62@gmail.com

Riccardo Mezzoprete  
riccardo.mezzoprete@tiscali.it

Nicola Logoluso  
nicola.logoluso@gmail.com

Lorenzo Drago  
lorenzo.drago@unimi.it

<sup>1</sup> Orthopaedic Surgery and Trauma, Medical School, University of Thessaly, Larissa, Greece

<sup>2</sup> Department for Trauma Surgery, Medical University, Innsbruck, Austria

<sup>3</sup> Department for Orthopaedics, San Luca Hospital, Vallo Della Lucania, Italy

<sup>4</sup> Department for Orthopaedics, San Camillo de Lellis Hospital, Rieti, Italy

<sup>5</sup> Department of Reconstructive Surgery of Osteo-articular Infections CRIO Unit, IRCCS Galeazzi Orthopaedic Institute, Via R. Galeazzi 4, 20161 Milan, Italy

<sup>6</sup> Laboratory of Clinical Chemistry and Microbiology, IRCCS Galeazzi Orthopaedic Institute, Milan, Italy


<sup>7</sup> Laboratory of Medical Technical Sciences, Department of Biochemical Sciences for Health, University of Milano, Milan, Italy

## Study profile:

- Condition: Closed fresh fractures of long bones requiring the use of plates or intramedullary nails
- Intervention: Intraoperative application of DAC® + Antibacterial Agent
- Study design: Single blind - randomised - controlled - multicentre
- Endpoint Classification: safety and efficacy study
- Primary outcome measures:
  - clinical and laboratory evidence of safety
  - clinical and laboratory evidence of efficacy
- Level of evidence II


## Risk profile:

In both groups approximately half of the patients presented with one or more relevant co-morbidities known to increase postsurgical infection risk (McPherson's classification)



## DAC® Effectiveness Evidence :

Six surgical site infections were reported in the control group (4.7%), compared to none in the treated group (P=0.02) at 18 months follow-up. 75% of control group host type C developed surgical site infection.



## Study population:

253 patients

- 126 treated group- internal osteosynthesis and DAC®
  - 127 control group- internal osteosynthesis
- Mean age (years): 58.6 ±17.6 (control) and 62.5±21.2 (treated)

TYPE OF FIXATION	CONTROLS	%	TREATED	%
PLATE/SCREW	117	92.1	115	91.3
INTRAMEDULLARY NAIL	10	7.9	11	8.7

## Fracture site:

FRACTURE SITE	CONTROLS	%	TREATED	%
FEMUR	32	25.2	47	37.3
TIBIA/KNEE	11	8.7	16	12.7
ANKLE/FOOT	29	22.8	32	25.4
CLAVICLE	11	8.7	10	7.9
HUMERUS	8	6.3	6	4.8
FOREARM/WRIST	29	22.8	14	11.1
HAND	7	5.5	1	0.8

**Conclusions** About 50% of the enrolled patients presenting one or more co-morbidities. The results are very encouraging with 4.7% of the control group presenting with infection, versus 0% in the treated group (P<0.02).



## One-stage exchange with antibacterial hydrogel coated implants provides similar results to two-stage revision, without the coating, for the treatment of peri-prosthetic infection

Nicola Capuano<sup>1</sup> · Nicola Logoluso<sup>2</sup> · Enrico Gallazzi<sup>2</sup> · Lorenzo Drago<sup>3</sup> · Carlo Luca Romanò<sup>2</sup>

Received: 23 March 2017 / Accepted: 12 March 2018

© European Society of Sports Traumatology, Knee Surgery, Arthroscopy (ESSKA) 2018

- <sup>1</sup> Department for Orthopaedics, San Luca Hospital, Vallo della Lucania, Italy
- <sup>2</sup> Department of Reconstructive Surgery of Osteo-articular Infections, I.R.C.C.S. Galeazzi Orthopaedic Institute, Via R. Galeazzi 4, 20161 Milan, Italy
- <sup>3</sup> Laboratory of Clinical Chemistry and Microbiology, I.R.C.C.S. Galeazzi Orthopaedic Institute, Milan, Italy

### Level of evidence III.

**Methods** In this two-center case-control, study, **22 patients**, treated with a one-stage procedure, using implants coated with an antibiotic-loaded hydrogel [defensive antibacterial coating (DAC<sup>®</sup>)], were compared with **22 retrospective matched controls**, treated with a two-stage revision procedure, without the coating.

**Results** At a mean follow-up of  $29.3 \pm 5.0$  months, two patients (9.1%) in the DAC<sup>®</sup> group showed an infection recurrence, compared to three patients (13.6%) in the two-stage group. Clinical scores were similar between groups, while average hospital stay and antibiotic treatment duration were significantly reduced after one-stage, compared to two-stage ( $18.9 \pm 2.9$  versus  $35.8 \pm 3.4$  and  $23.5 \pm 3.3$  versus  $53.7 \pm 5.6$  days, respectively).

### Conclusions

Although in a relatively limited series of patients, our data shows similar infection recurrence rate after one-stage exchange with DAC<sup>®</sup>-coated implants, compared to two-stage revision without coating, with reduced overall hospitalization time and antibiotic treatment duration.



## Two-stage cementless hip revision for peri-prosthetic infection with an antibacterial hydrogel coating: results of a comparative series

Luigi Zagra<sup>1</sup> · Enrico Gallazzi<sup>1</sup> · Delia Romanò<sup>2</sup> · Sara Scarponi<sup>2</sup> · Carlo Romanò<sup>3</sup>

Received: 6 October 2018 / Accepted: 12 October 2018  
 © SICOT aisbl 2018

- <sup>1</sup> Hip Department, IRCCS Istituto Ortopedico Galeazzi, Via R. Galeazzi 4, 20161 Milan, Italy
- <sup>2</sup> Department of Reconstructive Surgery of Osteo-articular Infections, IRCCS Istituto Ortopedico Galeazzi, Milan, Italy
- <sup>3</sup> Centro Medico, Corso Venezia 2, 20121 Milan, Italy

**Methods** In this case-control study, 27 patients, treated with a two-stage procedure, using cementless implants coated with an antibiotic-loaded hydrogel (DAC®, “Defensive Antibacterial Coating”), were compared with 27 matched controls, treated with a two-stage cementless revision procedure, without the coating.

**Results** At a mean follow-up of 2.7 (minimum 2.1–maximum 3.5) years, no evidence of infection, implant loosening, or adverse events were observed in the DAC®-treated group, compared to four cases of infection recurrence in the control group.

	DAC® (N=27)	Controls (N=27)
Harris Hip Score	84.6 ± 15.8	81.6 ± 15.2
Hospital stay incl. rehabilitation (days)	28.2 ± 3.9	33.8 ± 5.4
Hip dislocation	1	1
Delayed wound healing	0	1
Infection	0	4 (14.8%)

## Conclusions

Although in a relatively limited series of patients our data show that cementless two-stage hip revision, performed with an antibacterial hydrogel coating, may provide better infection control than two-stage without the coating, with reduced hospitalization time, these findings warrant further studies in the possible applications of antibacterial coating technologies to treat implant-related infections.





## Article

# Antibiotic-Loaded Hydrogel Coating to Reduce Early Postsurgical Infections in Aseptic Hip Revision Surgery: A Retrospective, Matched Case-Control Study

Daniele De Meo <sup>1,\*</sup> , Valeria Calogero <sup>1</sup> , Lorenzo Are <sup>1</sup> , Armando U. Cavallo <sup>2</sup>,  
Pietro Persiani <sup>1</sup> and Ciro Villani <sup>1</sup>

<sup>1</sup> Department of Orthopaedic and Traumatology, Policlinico Umberto I Hospital - Sapienza University of Rome, Piazzale A. Moro, 3, 00185 Rome, Italy; valeria.calog@gmail.com (V.C.); lorenzo.are0@gmail.com (L.A.); ppersiani@me.com (P.P.); ciro.villani@uniroma1.it (C.V.)

<sup>2</sup> Department of Biomedicine and Prevention, Tor Vergata University, Via Cracovia, 50, 00133 Rome, Italy; armandocavallo90@gmail.com

\* Correspondence: dannydemeo@hotmail.com; Tel.: +39-333-874-5373

Received: 28 February 2020; Accepted: 13 April 2020; Published: 15 April 2020



## Abstract

Periprosthetic joint infections (PJIs) are a cause of frequent implant failure in revision hip replacement surgery. The purpose of this study is to evaluate the onset of early postoperative infections in patients who underwent hip surgery with cementless prostheses treated with an antibiotic loaded hydrogel on their surface, in addition to systemic prophylaxis, and compare them to a control group. The secondary objective was to evaluate the onset of any local and systemic adverse effects and interference with bone ingrowth processes and functional recovery. A retrospective observational study was conducted on patients who underwent revision hip surgery by performing a 1:1 match between patients treated with an antibiotic hydrogel (ALH) and the control patients. The incidence of PJIs was assessed with a minimum of six months follow-up. Seventeen patients treated with the ALH were compared with 17 patients from the control group. No PJIs were reported in the ALH group versus the six cases encountered in the control group ( $p < 0.0001$ ). No significant differences were reported with regard to prosthetic osseointegration and functional results, nor were there side effects in the ALH group.


## Conclusions

Despite the low sample size, the use of on-site prophylaxis with ALH has proven effective and safe in reducing the risk of PJIs in patients with a high risk for infections. Further studies are needed to validate these results in other implant-related surgeries.



## Defensive antibacterial coating in revision total hip arthroplasty: new concept and early experience

Massimo Franceschini<sup>1</sup>, N Amir Sandiford<sup>2</sup>, Vincenzo Cerbone<sup>1</sup>,  
Lucio Cappelli Toledo de Araujo<sup>3,4</sup> and Daniel Kendoff<sup>4</sup>

HIP International  
2020, Vol. 30(1S) 7–11  
© The Author(s) 2020  
Article reuse guidelines:  
[sagepub.com/journals-permissions](https://sagepub.com/journals-permissions)  
DOI: 10.1177/1120700020917125  
[journals.sagepub.com/home/hpi](https://journals.sagepub.com/home/hpi)  


### Abstract

**Background:** Infections remains the most feared complication in total hip arthroplasty (THA). New strategies of PJI prevention includes coating of conventional implants. Defensive Antibacterial Coating (DAC®), an antibacterial hydrogel coating made of hyaluronan, poly-D and L-lactide can protect biomaterials as an effective barrier at the time of implantation. In addition, it can be used with topical antibiotics to prevent early colonisation of the implant.

**Scope:** This manuscript describes the detailed function of the DAC® in general as well as an analysis of its use in revision THA in a series of 28 patients in a short-term follow-up. Its use in patients undergoing cementless re-implantation after 2-staged procedures in THA is described in detail within the manuscript.

### Conclusions

DAC® found to be effective in terms of infection control and safety in our patient cohort and has been expanded for cementless 1-staged revisions in PJI of the hip in our institution.



## Antibacterial hydrogel coating in joint mega-prosthesis: results of a comparative series

Carmine Zoccali<sup>1</sup> · Guido Scoccianti<sup>2</sup> · Roberto Biagini<sup>1</sup> · Primo Andrea Daolio<sup>3</sup> · Fabio Luca Giardina<sup>3</sup> · Domenico Andrea Campanacci<sup>2</sup>

Received: 22 November 2020 / Accepted: 18 January 2021

© The Author(s), under exclusive licence to Springer-Verlag France SAS part of Springer Nature 2021

### Abstract

**Purpose** Joint mega-prosthesis after bone tumors, severe trauma or infection is associated with high rates of post-surgical septic complications. A fast-resorbable antibacterial hydrogel coating (DAC®, Defensive Antibacterial Coating) has previously been shown to be able to significantly reduce surgical site infection in various clinical settings. Aim of the present study was to evaluate the safety and efficacy of the DAC® hydrogel coating to prevent early periprosthetic joint infection after joint mega-prosthesis.

**Methods** In this three-centers, case–control study, 43 patients, treated with an antibacterial hydrogel coated mega-prosthesis for oncological ( $N = 39$ ) or non-oncological conditions ( $N = 4$ ), were retrospectively compared with 43 matched controls, treated with mega-implants without the coating. Clinical, laboratory and radiographic examinations were performed to evaluate the occurrence of post-surgical infection, complications and adverse events. Results At a mean follow-up of 2 years, no evidence of infection or adverse events were observed in the DAC®-treated group, compared to six cases of post-surgical infection in the control group.

### Conclusions

This matched case–control study shows that a fast-resorbable, antibiotic-loaded coating can be safely used to protect joint mega-prosthesis, providing a reduction of early surgical site infections with no side effects. Larger prospective trials with longer follow-ups are warranted to confirm this report.

# Antibiotic-Loaded Hydrogel Coating for the Prevention of Local Infection after Vertebral Surgery: A Retrospective Cohort Analysis

GIOVANNI PARBONETTI, MD<sup>1</sup>  
HEAD OF THE DEPARTMENT OF NEUROSURGERY

ADRIANA PUGLISI, MD<sup>1</sup>  
CONSULTANT SURGEON

BRUNO RIZZO, MD<sup>1</sup>  
CONSULTANT SURGEON

EROS LA MAIDA, MD<sup>1</sup>  
CONSULTANT SURGEON

ROBERTO GRANATA, MD<sup>2</sup>  
CONSULTANT SURGEON

<sup>1</sup> NEUROSURGERY DIVISION, SAN LUCA HOSPITAL, LUCANIA, ITALY.

<sup>2</sup> NEUROSURGERY DIVISION, DEL MARE HOSPITAL, NAPOLI, ITALY

## Abstract

**Background:** To preliminarily assess the effectiveness of a highly viscous antibiotic-loaded hydrogel used as a coating for the prevention of a superficial and deep Surgical Site Infections (SSIs) after laminectomy and fusion in instrumented vertebral surgery.

**Methods:** We performed a retrospective cohort analysis on 73 consecutive patients who underwent surgery from June 2018 to December 2019 for degenerative spinal disorders (DSD) or traumatic fractures with segmental instability. Patients received the antibiotic-loaded hydrogel over the implants perioperatively and were observed postoperatively for 12 months.


**Results:** Postoperative evaluations showed no adverse events in the study population. None of the patients reported significant pain or functional limitation after surgery. Post-surgically, computed tomography scans confirmed the correct positioning of instruments. At 12 months follow-up, no infection was recorded in the overall population.

## Conclusions

This retrospective investigation highlights the importance of adopting measures to prevent SSIs in instrumented vertebral surgery. The intraoperative local use of an antibiotic-loaded hydrogel, complementary to systemic antibiotic therapy, appears to minimize the risk of superficial and deep infection.

# DAC<sup>®</sup>

DEFENSIVE ANTIBACTERIAL COATING



## **DAC<sup>®</sup> USAGE IMPACT ON HEALTHCARE COSTS \***

\* ALL THE CLINICAL PAPERS SUMMARIZED IN THIS SECTION CAN BE FOUND AND REVIEWED IN THE "SCIENTIFIC REFERENCES" SECTION OF THE DAC<sup>®</sup> WEBSITE [WWW.DAC-COATING.COM](http://WWW.DAC-COATING.COM)



Contents lists available at ScienceDirect

The Journal of Arthroplasty

journal homepage: [www.arthroplastyjournal.org](http://www.arthroplastyjournal.org)



## Economic Evaluation of Antibacterial Coatings on Healthcare Costs in First Year Following Total Joint Arthroplasty

Maria Teresa Trentinaglia, PhD <sup>a, b</sup>, Catherine Van Der Straeten, MD <sup>c</sup>, Ilaria Morelli, MD <sup>d</sup>, Nicola Logoluso, MD <sup>e</sup>, Lorenzo Drago, MD, PhD <sup>f</sup>, Carlo L. Romanò, MD <sup>e, \*</sup>

<sup>a</sup> Department of Economics, Università Commerciale Luigi Bocconi, Milan, Italy

<sup>b</sup> Department of Environmental Science and Policy, Università degli Studi di Milano, Milan, Italy

<sup>c</sup> Musculoskeletal Sciences and Technology Lab, Department of Surgery and Cancer, Imperial College London, London, UK

<sup>d</sup> Università degli Studi di Milano - IRCCS Istituto Ortopedico Galeazzi, U.O. di Ortopedia Pediatrica, Medico Specializzando, Milan, Italy

<sup>e</sup> Centre for Reconstructive Surgery and Osteo-Articular Infections C.R.I.O. Unit, IRCCS Galeazzi Institute, Milan, Italy

<sup>f</sup> Laboratory of Clinical-Chemistry and Microbiology, IRCCS Galeazzi Institute, and SCIBIS Department, University of Milan, Milan, Italy

### Abstract

**Background:** Antibacterial coatings (ABCs) of implants have proven safe and effective to reduce post-surgical infection, but little is known about their possible economic impact on large-scale use. This study evaluated the point of economic balance, during the first year after surgery, and the potential overall annual healthcare cost savings of 3 different antibacterial technologies applied to joint arthroplasty: a dual-antibiotic-loaded bone cement (COPAL G<sup>®</sup>), an antibacterial hydrogel coating (DAC<sup>®</sup>), and a silver coating (Agluna).

**Methods:** The variables included in the algorithm were average cost and number of primary joint arthroplasties; average cost per patient of the ABC; incidence of periprosthetic joint infections and expected reduction using the ABCs; average cost of infection treatment and expected number of cases.

**Results:** The point of economic balance for COPAL G<sup>®</sup>, DAC<sup>®</sup>, and Agluna in the first year after surgery was reached in patient populations with an expected postsurgical infection rate of 1.5%, 2.6%, and 19.2%, respectively. If applied on a national scale, in a moderately high-risk population of patients with a 5% expected postsurgical infection rate, COPAL G<sup>®</sup> and DAC<sup>®</sup> hydrogel would provide annual direct cost savings of approximately V48,800,000 and V43,200,000 (V1220 and V1080 per patient), respectively, while the silver coating would be associated with an economic loss of approximately V136,000,000.

### Conclusions

This economic evaluation shows that ABC technologies have the potential to decrease healthcare costs primarily by decreasing the incidence of surgical site infections, provided that the technology is used in the appropriate risk class of patients.



## References

1. Parisi TJ, Konopka JF, Bedair HS. What is the Long-term Economic Societal Effect of Periprosthetic Infections After THA? A Markov Analysis. *Clin Orthop Relat Res*. 2017 Jul;475(7):1891-1900.
2. Bonneville P, Bonnomet F, Philippe R, Loubignac F, Rubens-Duval B, Talbi A, Le Gall C, Adam P; SOFCOT. Early surgical site infection in adult appendicular skeleton trauma surgery: a multicenter prospective series. *Orthop Traumatol Surg Res*. 2012 Oct;98(6):684-9.
3. Oliveira PR, Carvalho VC, da Silva Felix C, de Paula AP, Santos-Silva J, Lima AL. The incidence and microbiological profile of surgical site infections following internal fixation of closed and open fractures. *Rev Bras Ortop*. 2016 Feb 2;51(4):396-9.
4. Springer BD, Cahue S, Etkin CD, Lewallen DG, McGrory BJ. Infection burden in total hip and knee arthroplasties: an international registry-based perspective. *Arthroplast Today*. 2017;3(2):137-140. Published 2017 Jun 20. doi:10.1016/j.artd.2017.05.003.
5. Gundtoft PH, Pedersen AB, Varnum C, Overgaard S. Increased Mortality After Prosthetic Joint Infection in Primary THA. *Clin Orthop Relat Res*. 2017;475(11):2623-2631. doi:10.1007/s11999-017-5289-6.
6. Edwards C, Counsell A, Boulton C, Moran CG. Early infection after hip fracture surgery: risk factors, costs and outcome. *J Bone Joint Surg Br*. 2008 Jun;90(6):770-7. doi: 10.1302/0301-620X.90B6.20194.
7. Garrido-Gomez J, Arrabal-Polo MA, Girón-Prieto MS, Cabello-Salas J, Torres-Barroso J, Parra-Ruiz J. Descriptive analysis of the economic costs of periprosthetic joint infection of the knee for the public health system of Andalusia. *J Arthroplasty* 2013;28:1057e60.
8. Kapadia BH, Johnson AJ, Issa K, Mont MA. Economic evaluation of chlorhexidine cloths on healthcare costs due to surgical site infections following total knee arthroplasty. *J Arthroplasty* 2013;28:1061e5.
9. Romanò CL, Scarponi S, Gallazzi E, Romanò D, Drago L (2015) Antibacterial coating of implants in orthopaedics and trauma: a classification proposal in an evolving panorama, *J Orthop Surg Res*. 2015; 10: 157
10. Pitarresi G, Palumbo FS, Calascibeta F, Fiorica C, Di Stefano M, Giammona G. Medicated hydrogels of hyaluronic acid derivatives for use in orthopedic field. *International Journal of Pharmaceutics*. 2013 Jun 5;449(1-2):84-94.
11. Drago L, Boot W, Dimas K, Malizos K, Hänsch GM, Stuyck J, Gawlita D, Romanò CL. Does implant coating with antibacterial-loaded hydrogel reduce bacterial colonization and biofilm formation in vitro ? *Clinical Orthopaedics and Related Research*. 2014 Nov;472(11):3311-3323
12. Romanò CL, De Vecchi E, Bortolin M, Morelli I, Drago L. Hyaluronic acid and its composites as a local antimicrobial/antiadhesive barrier. *Journal of Bone and Joint Infection*. 2017;2(1):63-72
13. Giammona G, Pitarresi G, Palumbo FS, Maraldi S, Scarponi S, Romanò CL. (2018). Hyaluronic-Based Antibacterial Hydrogel Coating for Implantable Biomaterials in Orthopedics and Trauma: From Basic Research to Clinical Applications. 10.5772/intechopen.73203.
14. Giavaresi G, Meani E, Sartori M, Ferrari A, Bellini D, Sacchetta AC, Meraner J, Sambri A, Vocale C, Sambri V, Fini M, Romanò CL. Efficacy of antibacterial-loaded coating in an in vivo model of acutely highly contaminated implant. *Int Orthop*. 2014 Jul;38(7):1505-12.
15. Boot W, Gawlitta D, Nikkels PGJ, et al. Hyaluronic Acid-Based Hydrogel Coating Does Not Affect Bone Apposition at the Implant Surface in a Rabbit Model. *Clin Orthop Relat Res*. 2017;475(7):1911-1919.
16. Romanò CL, Malizos K, Capuano N, Mezzoprete R, D'Arienzo M, Van Der Straeten C, Scarponi S, Drago L. Does an Antibiotic-Loaded Hydrogel Coating Reduce Early Post-Surgical Infection After Joint Arthroplasty? *J Bone Jt Infect*. 2016 Jul 19;1:34-41.
17. Malizos K, Blauth M, Danita A, Capuano N, Mezzoprete R, Logoluso N, Drago L, Romanò CL. Fast-resorbable antibiotic-loaded hydrogel coating to reduce post-surgical infection after internal osteosynthesis: a multicenter randomized controlled trial. *J Orthop Traumatol*. 2017 Jun;18(2):159-169.
18. Capuano N, Logoluso N, Gallazzi E, Drago L, Romanò CL. One-stage exchange with antibacterial hydrogel coated implants provides similar results to two-stage revision, without the coating, for the treatment of peri-prosthetic infection. *Knee Surg Sports Traumatol Arthrosc*. 2018 Nov;26(11):3362-3367.
19. Zagra L, Gallazzi E, Romanò D, Scarponi S, Romanò C. Two-stage cementless hip revision for peri-prosthetic infection with an antibacterial hydrogel coating: results of a comparative series. *Int Orthop*. 2019 Jan;43(1):111-115.
20. Trentinaglia MT, Van Der Straeten C, Morelli I, Logoluso N, Drago L, Romanò CL. Economic Evaluation of Antibacterial Coatings on Healthcare Costs in First Year Following Total Joint Arthroplasty. *J Arthroplasty*. 2018 Jun;33(6):1656-1662.
21. Romanò CL, Logoluso N, Trentinaglia, MT, Romanò E. Economic impact of an antibacterial hydrogel coating in primary joint arthroplasty: a Markov expected utility analysis. Abstract 39th SICOT World Congress, October 10-13, 2018, Montreal, Canada.
22. George DA, Gant V, Haddad FS. The management of periprosthetic infections in the future: a review of new forms of treatment. *Bone Joint J*. 2015 Sep;97-B(9):1162-9.

**DAC**®  
DEFENSIVE ANTIBACTERIAL COATING



[www.dac-coating.com](http://www.dac-coating.com)

 **NOVAGENIT**™



[www.novagenit.com](http://www.novagenit.com)

### **List of reference videos**

<http://www.dac-coating.com/dac/video/>

<http://www.novagenit.com.au/dac/dac-videos>

<http://www.novagenit.com.au/dac/what-is-dac>

<http://www.dac-coating.com/dac/dac-barrier-effect/>

